Fidia has implemented a series of measures, to minimize any potential risks related with the COVID-19 outbreak, guaranteeing full operations in, from and to the factories, as well as transports of goods and supply of materials.

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Florham Park, N.J., December 2, 2019 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Florham Park, NJ, March 12, 2019 – NuDYN™ is the First Product in Fidia’s New Orthobiologics Portfolio; A Novel Acellular Amnion-Derived Injectable Allograft

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Efficacy and tolerability results with Oncofid®P-B in patients with papillary bladder cancer No new drug treatments for primary or recurrent papillary bladder cancer in 15 years Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and patented by Fidia farmaceutici, a leading Italian pharmaceutical multinational company Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021
PARSIPPANY, N.J., June 28, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

PARSIPPANY, NJ, May 8, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) – based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

HYMOVIS® has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies. PARSIPPANY, NJ., March 22, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) – based products and […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

FIDIA PHARMA USA INC. Introduces New Product Packaging for HYALO GYN® Featuring a Fresh, Feminine Look PARSIPPANY, N.J., Dec. 7, 2016 – Many women suffer silently from the bothersome symptoms associated with vaginal dryness. Vaginal dryness can have many origins, including childbirth, breast-feeding, menopause, chemotherapy, oral contraceptive use and stress.1 Vaginal hydrating gels, such as […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

PARSIPPANY, N.J., Nov. 28, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA INC., introduces newly redesigned packaging for the vaginal hydrating gel, HYALO GYN®. While keeping its current formulation, HYALO GYN®’s new product packaging gives the […]

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness